Financing ·
Niki BioSolutions establishes ATM program to sell up to $1.4M of common stock
APMNiki BioSolutions, Inc.
Niki BioSolutions, Inc. entered into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC and Brookline Capital Markets on October 9, 2026. The agreement allows the company to sell shares of its common stock from time to time through these sales agents for an aggregate maximum offering price of up to $1,396,000. H.C. Wainwright will act as the primary sales agent, while Brookline Capital Markets serves as a qualified independent underwriter to address conflicts of interest involving Wainwright's managing director who is also a company director and shareholder. The company pays a 3% placement fee on gross sales price and may terminate the agreement with ten business days' notice. Niki BioSolutions operates in the biotechnology sector, focusing on developing biotherapeutics.